azelastine and Hay Fever studies

azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.

Research Excerpts

Excerpt	Relevance	Reference
"The results of this study indicate that the therapeutic use of azelastine eye drops in patients with seasonal allergic conjunctivitis or rhino-conjunctivitis can be recommended."	9.10	Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. ( Campbell, LM; Ellers-Lenz, B; Fell, PJ; Harrison, JM; James, IG; Petzold, U, 2003)
"In a randomised, multicentre study, the effect of azelastine eye drops (n = 51 patients) was compared in a double-blind manner with placebo eye drops (n = 30 patients) and in an open manner with levocabastine eye drops (n = 32 patients) during a 14-day treatment period involving 113 children (aged 4 to 12 years) suffering from seasonal allergic conjunctivitis/rhinoconjunctivitis."	9.08	Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. ( Marzetto, M; Sabbah, A, 1998)
"05% azelastine eye drops twice daily administered for 14 days to patients with seasonal allergic conjunctivitis or rhinoconjunctivitis."	9.08	Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. ( Lenhard, G; Mivsek-Music, E; Obtulowicz, K; Perrin-Fayolle, M; Secchi, A, 1997)
"05% azelastine eye-drops in patients with seasonal allergic conjunctivitis of > or = 1 year's duration."	9.08	Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. ( Giede-Tuch, C; Westhoff, M; Zarth, A, 1998)
"A retrospective study was conducted to investigate the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3)."	8.31	Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels. ( Liu, S; Liu, Y; Lu, SF; Zang, GM, 2023)
" It is hypothesized that the platelet activating factor receptor antagonist ginkgolide B (GB) and the carotenoid antioxidant astaxanthin (ASX) interact with antihistamines cetirizine dihydrochloride (CTZ) and azelastine (AZE) to potentiate their ability to downregulate potentially pathological immune activation."	5.38	In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012)
"The results of this study indicate that the therapeutic use of azelastine eye drops in patients with seasonal allergic conjunctivitis or rhino-conjunctivitis can be recommended."	5.10	Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. ( Campbell, LM; Ellers-Lenz, B; Fell, PJ; Harrison, JM; James, IG; Petzold, U, 2003)
"In a randomised, multicentre study, the effect of azelastine eye drops (n = 51 patients) was compared in a double-blind manner with placebo eye drops (n = 30 patients) and in an open manner with levocabastine eye drops (n = 32 patients) during a 14-day treatment period involving 113 children (aged 4 to 12 years) suffering from seasonal allergic conjunctivitis/rhinoconjunctivitis."	5.08	Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. ( Marzetto, M; Sabbah, A, 1998)
"05% azelastine eye drops twice daily administered for 14 days to patients with seasonal allergic conjunctivitis or rhinoconjunctivitis."	5.08	Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. ( Lenhard, G; Mivsek-Music, E; Obtulowicz, K; Perrin-Fayolle, M; Secchi, A, 1997)
"05% azelastine eye-drops in patients with seasonal allergic conjunctivitis of > or = 1 year's duration."	5.08	Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. ( Giede-Tuch, C; Westhoff, M; Zarth, A, 1998)
"Intranasal azelastine hydrochloride (Astelin, Meda Pharmaceuticals, Somerset, NJ, USA) is a first-line treatment for allergic and non-allergic vasomotor rhinitis with well-established therapeutic efficacy and safety."	4.85	Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis. ( Berger, WE, 2009)
"A retrospective study was conducted to investigate the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3)."	4.31	Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels. ( Liu, S; Liu, Y; Lu, SF; Zang, GM, 2023)
" Azelastine bioavailability was similar for MP29-02 and Astelin®."	2.77	Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. ( Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012)
"Olopatadine, an antihistamine used in allergic conjunctivitis, is under development as a nasal preparation for the treatment of allergic rhinitis."	2.73	The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. ( Costantini, C; Drake, M; Pipkorn, P; Proud, D; Reynolds, C; Sanico, A; Togias, A; Wall, M, 2008)
"Desloratadine was significantly better than placebo (p < 0."	2.72	Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. ( Horak, F; Kavina, A; Marschall, K; Munzel, U; Petzold, U; Zieglmayer, R; Zieglmayer, UP, 2006)
"Azelastine nasal spray is an effective treatment for patients with seasonal allergic rhinitis who do not respond to loratadine and is an alternative to switching to another oral antihistamine or to using multiple antihistamines."	2.71	Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. ( Berger, WE; White, MV, 2003)
"Azelastine nasal spray was reported to control all rhinitis symptoms, including nasal congestion, regardless of rhinitis diagnosis during the 2-week study period."	2.71	Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. ( Kaliner, MA; Lieberman, P; Wheeler, WJ, 2005)
"The objective of the present study was to compare the efficacy and tolerability of azelastine nasal spray administered at the recommended dosage of 2 sprays per nostril twice daily with those of cetirizine in the treatment of moderate to severe SAR."	2.71	Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. ( Berger, W; Bernstein, J; Corren, J; Nayak, A; Sacks, H; Storms, W, 2005)
"Treatment with azelastine had no effect on the levels of albumin, interleukin-4, interleukin-5, intercellular adhesion molecule-1, tumor necrosis factor-alpha, and eosinophil cationic protein during the late-phase response."	2.70	Effects of intranasal azelastine on the response to nasal allergen challenge. ( Assanasen, P; Baroody, FM; deTineo, M; Haney, L; Naclerio, RM; Saengpanich, S, 2002)
"Azelastine, however, was statistically superior in efficacy as well as in safety (PWei-Lachin < 0."	2.70	Comparative efficacy and safety of azelastine and levocabastine nasal sprays in patients with seasonal allergic rhinitis. ( Baehre, M; Falser, N; Rahlfs, VW; Wober, W, 2001)
"Treatment with azelastine (4 mg/os once daily) inhibited immediate reactions to allergens by 65% (range 55-74) and to histamine by 68% (range 47-82)."	2.69	Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. ( Bähre, M; De Weck, AL; Derer, T, 2000)
"Azelastine hydrochloride is an H1-receptor antagonist with antiinflammatory properties that is available in the US as Astelin Nasal Spray for the treatment of seasonal allergic rhinitis."	2.69	Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. ( Berger, WE; Fineman, SM; Lieberman, P; Miles, RM, 1999)
"Azelastine nasal spray is an effective and well-tolerated drug in the treatment of seasonal allergic rhinitis."	2.69	[Clinical assessment of azelastine nasal spray in seasonal allergic rhinitis]. ( Arcimowicz, M; Samoliński, B; Zawisza, E, 1998)
" In 73% of children the administered dose of azelastine was one spray puff per nostril twice daily, corresponding to the recommended daily, dosage of 0."	2.68	Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age. ( Bähre, M; Diez Crespo, CD; Wober, W, 1997)
"Azelastine nasal spray was generally administered at a dose of one spray puff (0."	2.68	Efficacy and tolerability of azelastine nasal spray in the treatment of allergic rhinitis: large scale experience in community practice. ( Bähre, M; Diez Crespo, C; Wober, W, 1997)
"Azelastine is a powerful topical antihistamine, while budesonide appears to be a potent long-acting anti-inflammatory agent."	2.68	Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. ( Clement, P; De Waele, M; Smitz, J; Wang, D, 1997)
"Azelastine nasal spray demonstrated broad clinical antirhinitis activity that for the 2 sprays/nostril bid dosage regimen was consistently clinically and statistically significant."	2.68	Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. ( Chu, TJ; D'Eletto, TA; Dockhorn, RJ; Freitag, JJ; Kraemer, MJ; LaForce, C; Prenner, BM; Widlitz, MD, 1996)
"Azelastine-treated subjects had significantly fewer nasal symptoms during week 4 (p < 0."	2.68	Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. ( Chiapparino, A; Foresi, A; Hernandez, A; Marazzini, L; Mastropasqua, B; Pelucchi, A, 1995)
" Results showed that both antihistamines, applied topically of dosed orally, reduced sneezing even when significant increases of histamine concentration in nasal secretions were evidenced immediately after NAC."	2.68	The activity of recent anti-allergic drugs in the treatment of seasonal allergic rhinitis. ( Clement, P; De Waele, M; Smitz, J; Wang, D, 1996)
"56 mg/day) were equally effective in reducing clinical symptoms (p = NS), although the standard dosage required fewer additional puffs during times of peak pollen counts (p < 0."	2.68	Seasonal rhinitis and azelastine: long- or short-term treatment? ( Bagnasco, M; Bertolini, C; Canonica, GW; Ciprandi, G; Fiorino, N; Passalacqua, G; Ricca, V; Riccio, AM; Truffelli, T, 1997)
"Azelastine was well tolerated, and no subject discontinued therapy with azelastine due to an adverse experience."	2.68	Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis. ( Meltzer, EO; Weiler, JM, 1997)
"Azelastine is a selective H1-receptor antagonist, which has previously been demonstrated to be effective in the treatment of allergic rhinitis."	2.68	Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. ( Bagnasco, M; Buscaglia, S; Canonica, GW; Catrullo, A; Ciprandi, G; Fiorino, N; Montagna, P; Pesce, G, 1997)
" The groups that received 2 sprays of azelastine per nostril once and twice daily and the chlorpheniramine group had statistically significantly more improvement in total rhinitis symptoms than the placebo group without serious adverse events."	2.67	A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. ( Benson, PM; Freitag, J; Meltzer, EO; Weiler, JM; Weiler, K; Widlitz, MD, 1994)
"Azelastine is a novel antiallergy medication currently under investigation for the treatment of allergic rhinitis and asthma."	2.67	Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. ( Chervinsky, P; Freitag, JJ; Grossman, J; Halverson, PC; Pearlman, DS; Storms, WW; Widlitz, MD, 1994)
"Azelastine solution is a topically (nasal) administered antiallergy drug with a preclinical profile suggestive of efficacy in patients with allergic rhinitis."	2.67	A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. ( Findlay, SR; Freitag, JJ; Hampel, F; Ratner, PH; van Bavel, J; Widlitz, MD, 1994)
"Azelastine is a novel, investigational, antiallergy medication that inhibits the generation, release, and/or end-organ activity of multiple mediators of the inflammatory process in vitro and in vivo."	2.67	Azelastine nasal spray in the management of seasonal allergic rhinitis. ( Dockhorn, RJ; Freitag, JJ; Meltzer, EO; Weiler, JM; Widlitz, MD, 1994)
" Elicited, volunteered, and observed adverse experiences were recorded for each subject and compared among groups."	2.66	Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis. ( Campbell, BH; Connell, JT; Diamond, L; Donnelly, A; Hamilton, LH; Hemsworth, GR; Perhach, JL; Rosenthal, RR; Weiler, JM, 1988)
" Pharmacokinetic studies have revealed no drug-drug interactions but a discrete increase in bioavailability of fluticasone propionate which was considered clinically unimportant."	2.49	New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. ( Wolthers, OD, 2013)
"Azelastine is an effective, rapid-acting, and well-tolerated second-generation antihistamine that improves nasal symptoms associated with SAR and VMR."	2.44	Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. ( Bernstein, JA, 2007)
"Azelastine nasal spray was more efficacious than placebo in the treatment of allergic rhinitis."	2.44	Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. ( Lee, TA; Pickard, AS, 2007)
" A small effect on growth has been reported in one study in children receiving a standard dosage over 1 year, however."	2.42	Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. ( Howarth, PH; Salib, RJ, 2003)
"Nonallergic rhinitis is a common disease that probably affects as many as 17 million Americans."	2.41	Update on nonallergic rhinitis. ( Lieberman, P; Settipane, RA, 2001)
"Azelastine was well tolerated in clinical trials and postmarketing surveys."	2.40	Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. ( McNeely, W; Wiseman, LR, 1998)
"Azelastine nasal spray is a topical antihistamine treatment for the symptoms of seasonal allergic rhinitis."	2.40	Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. ( Lieberman, P, 1999)
"Azelastine has a rapid onset of action with a benefit in about 2 hours and a prolonged duration of activity (12 to 24 hours)."	2.40	Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. ( Craig, TJ; Golden, SJ, 1999)
" It is hypothesized that the platelet activating factor receptor antagonist ginkgolide B (GB) and the carotenoid antioxidant astaxanthin (ASX) interact with antihistamines cetirizine dihydrochloride (CTZ) and azelastine (AZE) to potentiate their ability to downregulate potentially pathological immune activation."	1.38	In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012)
"CD14+ cells prepared from patients with pollinosis to Japanese cedar pollen were stimulated with specific allergen extracted from Japanese cedar pollen (Cry j 1) in the presence of azelastine (AZE), ketotifen (KET), fexofenadine (FEX) and oxatomide (OXA) for 6 days."	1.37	Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. ( Asano, K; Furuta, A; Hirano, K; Shoji, N; Suzaki, H, 2011)
"Azelastine was administered twice a day for 4 weeks in the pollen season."	1.30	[Efficacy of topical azelastine in the treatment of allergic rhinitis caused by Parietaria officinalis]. ( Biasi, D; Carletto, A; Lunardi, C; Maleknia, T; Pacor, ML, 1998)

Research

Studies (89)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.12)	18.7374
1990's	38 (42.70)	18.2507
2000's	31 (34.83)	29.6817
2010's	16 (17.98)	24.3611
2020's	3 (3.37)	2.80

Authors	Studies
Watts, AM	1
West, NP	1
Smith, PK	1
Zhang, P	1
Cripps, AW	1
Cox, AJ	1
Liu, Y	1
Liu, S	2
Lu, SF	1
Zang, GM	1
Meltzer, E	3
Ratner, P	2
Bachert, C	4
Carr, W	3
Berger, W	4
Canonica, GW	4
Hadley, J	1
Lieberman, P	7
Hampel, FC	2
Mullol, J	1
Munzel, U	5
Price, D	3
Scadding, G	1
Virchow, JC	1
Wahn, U	2
Murray, R	1
Bousquet, J	5
Wolthers, OD	1
May, U	1
Bernstein, J	4
Dahl, R	1
Demoly, P	1
Devillier, P	1
Hellings, P	1
Fokkens, W	1
Klimek, L	2
Ryan, D	1
Meltzer, EO	7
Amar, N	1
Fox, AT	1
Just, J	1
Muraro, A	1
Nieto, A	1
Valovirta, E	1
Wickman, M	1
Brixner, D	1
Morland, K	1
Carroll, CA	1
Lipworth, BJ	1
Pipkorn, P	1
Costantini, C	1
Reynolds, C	1
Wall, M	1
Drake, M	1
Sanico, A	1
Proud, D	1
Togias, A	1
Kelso, JM	1
Agarwal, MK	1
Vijayan, VK	1
Vermani, M	1
Berger, WE	4
Shah, SR	1
Nayak, A	2
Roland, P	1
Michael Wall, G	1
Kaliner, MA	2
Ratner, PH	3
Van Bavel, J	3
Amar, NJ	2
Daftary, P	2
Wheeler, W	3
Sacks, H	4
Shoji, N	1
Asano, K	1
Furuta, A	1
Hirano, K	1
Suzaki, H	1
Han, D	1
Chen, L	1
Cheng, L	1
Fu, Z	1
Zhang, W	1
Wang, C	1
Xi, L	1
Zhang, L	1
Baumann, D	1
Högger, P	1
Derendorf, H	1
Petzold, U	5
Maus, J	1
Mascher, H	1
Hermann, R	1
Mahmoud, FF	1
Haines, D	1
Al-Awadhi, R	1
Arifhodzic, N	1
Abal, A	1
Azeamouzi, C	1
Al-Sharah, S	1
Tosaki, A	1
Albu, S	1
Baschir, S	1
Yáñez, A	1
Rodrigo, GJ	1
Ciprandi, G	3
Cosentino, C	1
Milanese, M	1
Tosca, MA	1
James, IG	1
Campbell, LM	1
Harrison, JM	1
Fell, PJ	1
Ellers-Lenz, B	1
White, MV	1
Salib, RJ	1
Howarth, PH	1
Pearlman, DS	2
Grossman, J	2
Magnan, A	1
Uras, N	1
Karadag, A	1
Kurtaran, H	1
Yilmaz, T	1
LaForce, CF	1
Corren, J	3
Wheeler, WJ	2
Storms, W	1
Horak, F	2
Zieglmayer, UP	1
Zieglmayer, R	1
Kavina, A	1
Marschall, K	1
Hampel, F	3
Shah, S	1
Lee, TA	1
Pickard, AS	1
Bernstein, JA	1
Lumry, W	1
Prenner, B	1
Weiler, JM	4
Benson, PM	1
Weiler, K	1
Widlitz, MD	5
Freitag, J	1
Pelucchi, A	1
Chiapparino, A	1
Mastropasqua, B	1
Marazzini, L	1
Hernandez, A	1
Foresi, A	1
Dockhorn, RJ	2
Freitag, JJ	4
Gastpar, H	1
Nolte, D	1
Aurich, R	2
Brendt, P	1
Enzmann, H	1
Giesemann, G	1
Kunkel, G	1
Renz, W	1
Schata, M	1
Findlay, SR	1
Storms, WW	1
Chervinsky, P	1
Halverson, PC	1
Naclerio, RM	2
Dorow, P	1
LaForce, C	1
Prenner, BM	1
Chu, TJ	1
Kraemer, MJ	1
D'Eletto, TA	1
Wang, D	2
Clement, P	2
Smitz, J	2
De Waele, M	2
Charpin, D	1
Godard, P	1
Garay, RP	1
Baehre, M	4
Herman, D	1
Michel, FB	1
Conde Hernández, DJ	1
Palma Aqilar, JL	1
Delgado Romero, J	1
Passàli, D	2
Bellussi, L	2
Innocenti Paganelli, I	1
Finelli, F	1
Ricca, V	1
Passalacqua, G	1
Truffelli, T	1
Bertolini, C	1
Fiorino, N	2
Riccio, AM	1
Bagnasco, M	2
Buscaglia, S	1
Catrullo, A	1
Pesce, G	1
Montagna, P	1
Yamasaki, M	1
Matsumoto, T	1
Fukuda, S	1
Nakayama, T	1
Nagaya, H	1
Ashida, Y	1
Kyrein, HJ	1
Nirnberger, G	1
Rehn, D	1
Newson-Smith, G	1
Powell, M	1
Garnham, SP	1
MacMahon, MT	1
Wober, W	3
Diez Crespo, CD	1
Bähre, M	3
Diez Crespo, C	1
Lenhard, G	1
Mivsek-Music, E	1
Perrin-Fayolle, M	1
Obtulowicz, K	1
Secchi, A	1
Pacor, ML	1
Biasi, D	1
Carletto, A	1
Maleknia, T	1
Lunardi, C	1
McNeely, W	1
Wiseman, LR	1
Sabbah, A	1
Marzetto, M	1
Giede-Tuch, C	1
Westhoff, M	1
Zarth, A	1
Chicharro, JL	1
Lucía, A	1
Vaquero, AF	1
Pérez, M	1
Arcimowicz, M	1
Samoliński, B	1
Zawisza, E	1
Fineman, SM	1
Miles, RM	1
Golden, SJ	1
Craig, TJ	2
Kremer, B	1
Gülicher, D	1
Degen, M	1
Mösges, R	1
De Weck, AL	1
Derer, T	1
Portmann, D	1
Le Gal, M	1
Jessent, V	1
Verrière, JL	1
Settipane, RA	1
Falser, N	1
Rahlfs, VW	1
Duarte, C	1
Gharakhanian, S	1
Leynadier, F	1
Saengpanich, S	1
Assanasen, P	1
deTineo, M	1
Haney, L	1
Baroody, FM	1
Balzano, G	1
Gallo, C	1
Masi, C	1
Cocco, G	1
Ferranti, P	1
Melillo, E	1
Seccia, G	1
Lurie, A	1
Saudubray, F	1
Eychenne, JL	1
Venot, A	1
de Lauture, D	1
Dessanges, JF	1
Lockhart, A	1
Strauch, G	1
Thomas, KE	1
Ollier, S	1
Ferguson, H	1
Davies, RJ	1
Donnelly, A	1
Campbell, BH	1
Connell, JT	1
Diamond, L	1
Hamilton, LH	1
Rosenthal, RR	1
Hemsworth, GR	1
Perhach, JL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis[NCT00660517]	Phase 3	607 participants (Actual)	Interventional	2007-12-31	Completed
Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832]		20 participants	Interventional	2005-03-31	Completed
Acupuncture for Nasal Congestion in Allergic Rhinitis: An Open-Label, Randomized, Monocenter Trial (ANCAR Trial)[NCT05709977]		62 participants (Anticipated)	Interventional	2023-04-20	Recruiting
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection[NCT06008860]	Phase 4	280 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Proof of Concept Study to Evaluate Comparative Efficacy of an Azelastine/Fluticasone Combination Nasal Spray vs. Twice the Dose of Fluticasone in Persistent Allergic Rhinitis[NCT00845598]	Phase 4	0 participants (Actual)	Interventional	2010-08-31	Withdrawn (stopped due to Could not get IMP)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"change from baseline in the 12 hour instantaneous total nasal symptoms score(iTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period.~The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value." (NCT00660517)
Timeframe: day 1 to day 14

Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)

Intervention	units on a scale (Least Squares Mean)
Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg	-4.4
Azelastine Hcl 548 Mcg	-3.0
Fluticasone Propionate 200 Mcg	-3.5
Placebo	-1.7

change from baseline in the 12 hour reflective total nasal symptoms score(rTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value. (NCT00660517)
Timeframe: day 1 to day14

Change From Baseline in Adult ( Greater Than 18 Years of Age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days

Intervention	units on a scale (Least Squares Mean)
Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg	-5.3
Azelastine Hcl 548 Mcg	-3.3
Fluticasone Propionate 200 Mcg	-3.8
Placebo	-2.2

Change from Baseline in adult ( greater than 18 years of age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the end of 14 days The measurement scale is 0 to 24. A reduction in symptom severity score is indicated by a negative value. (NCT00660517)
Timeframe: day 1 to day 14

Article	Year
New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. Recent patents on inflammation & allergy drug discovery, 2013, Volume: 7, Issue:3 Topics: Administration, Intranasal; Adolescent; Adrenal Cortex Hormones; Adult; Androstadienes; Animals; Dru	2013
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:6 Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Drug Combinations; Humans; Phthala	2015
Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis. Expert opinion on drug metabolism & toxicology, 2009, Volume: 5, Issue:1 Topics: Administration, Intranasal; Aerosols; Biological Availability; Clinical Trials as Topic; Histamine A	2009
Azelastine and olopatadine in the treatment of allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 103, Issue:5 Topics: Administration, Intranasal; Anti-Allergic Agents; Clinical Trials as Topic; Dibenzoxepins; Humans; O	2009
Azelastine/fluticasone propionate(Dymista) for seasonal allergic rhinitis. The Medical letter on drugs and therapeutics, 2012, Oct-29, Volume: 54, Issue:1402 Topics: Androstadienes; Animals; Clinical Trials as Topic; Drug Combinations; Fluticasone; Humans; Nasal Spr	2012
Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:5 Topics: Administration, Intranasal; Administration, Topical; Adolescent; Adult; Aged; Androstadienes; Anti-A	2002
Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug safety, 2003, Volume: 26, Issue:12 Topics: Administration, Intranasal; Adrenal Cortex Hormones; Female; Histamine H1 Antagonists; Humans; Phtha	2003
Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy, 2007, Volume: 27, Issue:6 Topics: Administration, Intranasal; Anti-Allergic Agents; Cost-Benefit Analysis; Humans; Patient Satisfactio	2007
Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Current medical research and opinion, 2007, Volume: 23, Issue:10 Topics: Anti-Allergic Agents; Half-Life; Humans; Phthalazines; Randomized Controlled Trials as Topic; Rhinit	2007
Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs, 1998, Volume: 56, Issue:1 Topics: Administration, Intranasal; Adult; Beclomethasone; Budesonide; Child; Drug Tolerance; Glucocorticoid	1998
Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Histamine H1 Antagonists; Humans; Phthalazines; Randomized	1999
Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. The Journal of the American Osteopathic Association, 1999, Volume: 99, Issue:7 Suppl Topics: Administration, Inhalation; Histamine H1 Antagonists; Humans; Phthalazines; Rhinitis, Allergic, Pere	1999
Update on nonallergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 86, Issue:5 Topics: Adrenal Cortex Hormones; Adult; Age of Onset; Air Pollution; Anti-Inflammatory Agents, Non-Steroidal	2001

Article	Year
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. International archives of allergy and immunology, 2013, Volume: 161, Issue:4 Topics: Adult; Androstadienes; Anti-Allergic Agents; Cedrus; Disease Progression; Drug Combinations; Female;	2013
Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2016, Volume: 27, Issue:2 Topics: Caregivers; Child; Child, Preschool; Disease Progression; Drug Combinations; Female; Fluticasone; Hu	2016
The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 101, Issue:1 Topics: Adult; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzoxepins;	2008
Effect of azelastine nasal spray on histamine-and allergen-induced skin wheal response in patients with allergic rhinitis. The Journal of asthma : official journal of the Association for the Care of Asthma, 2008, Volume: 45, Issue:7 Topics: Administration, Intranasal; Adolescent; Adult; Anti-Allergic Agents; Child; Female; Histamine; Human	2008
Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clinical therapeutics, 2009, Volume: 31, Issue:1 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Dibenzoxepins; Dou	2009
Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010, Volume: 105, Issue:2 Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Aged; Allergens; Androstadienes; Cedrus; Ch	2010
A multicenter randomized double-blind 2-week comparison study of azelastine nasal spray 0.1% versus levocabastine nasal spray 0.05% in patients with moderate-to-severe allergic rhinitis. ORL; journal for oto-rhino-laryngology and its related specialties, 2011, Volume: 73, Issue:5 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-R	2011
Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. British journal of clinical pharmacology, 2012, Volume: 74, Issue:1 Topics: Administration, Intranasal; Adolescent; Adult; Androstadienes; Anti-Allergic Agents; Biological Avai	2012
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. The Journal of allergy and clinical immunology, 2012, Volume: 129, Issue:5 Topics: Administration, Intranasal; Adult; Androstadienes; Disease Progression; Drug Combinations; Female; F	2012
Intranasal phototherapy versus azelastine in the treatment of seasonal allergic rhinitis. Auris, nasus, larynx, 2013, Volume: 40, Issue:5 Topics: Administration, Intranasal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Mi	2013
Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:4 Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Co	2003
Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Current medical research and opinion, 2003, Volume: 19, Issue:4 Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-	2003
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Double-Blind Method; Dru	2003
Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:3 Topics: Administration, Intranasal; Adolescent; Adult; Anti-Allergic Agents; Child; Double-Blind Method; Fem	2003
Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Double-Blind Method; Drug Therapy, Combination; F	2004
Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Current medical research and opinion, 2005, Volume: 21, Issue:4 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Histamine H1	2005
Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clinical therapeutics, 2005, Volume: 27, Issue:5 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Cetirizine; Child; Double-Blind Method; Female;	2005
Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Current medical research and opinion, 2006, Volume: 22, Issue:1 Topics: Administration, Intranasal; Adolescent; Adult; Anti-Allergic Agents; Female; Histamine H1 Antagonist	2006
Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:3 Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Anti-Allergic Agents; Ant	2006
Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 99, Issue:3 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Double-Blind Metho	2007
Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 100, Issue:1 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Androstadienes; Bronchodilator Agents; Child; D	2008
A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. The Journal of allergy and clinical immunology, 1994, Volume: 94, Issue:6 Pt 1 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Child; Chlorpheniramine; Dose-Response Relation	1994
Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. The Journal of allergy and clinical immunology, 1995, Volume: 95, Issue:2 Topics: Administration, Intranasal; Adolescent; Adult; Beclomethasone; Bronchi; Bronchial Provocation Tests;	1995
Azelastine nasal spray in the management of seasonal allergic rhinitis. Annals of allergy, 1994, Volume: 72, Issue:4 Topics: Administration, Intranasal; Double-Blind Method; Drug Evaluation; Female; Histamine H1 Antagonists;	1994
Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy, 1994, Volume: 49, Issue:3 Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Ge	1994
A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. The Journal of allergy and clinical immunology, 1994, Volume: 94, Issue:5 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Bronchodilator Agents; Child; Double-Blind Meth	1994
Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear, nose, & throat journal, 1994, Volume: 73, Issue:6 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Child; Double-Blind Method; Female; Humans; Mal	1994
The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1993, Volume: 108, Issue:6 Topics: Capillary Permeability; Cetirizine; Cyproheptadine; Diphenhydramine; Double-Blind Method; Histamine	1993
Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. Arzneimittel-Forschung, 1993, Volume: 43, Issue:8 Topics: Administration, Intranasal; Adult; Aerosols; Bronchodilator Agents; Budesonide; Double-Blind Method;	1993
Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:2 Topics: Administration, Intranasal; Adolescent; Adult; Child; Double-Blind Method; Female; Histamine H1 Anta	1996
The activity of recent anti-allergic drugs in the treatment of seasonal allergic rhinitis. Acta oto-rhino-laryngologica Belgica, 1996, Volume: 50, Issue:1 Topics: Adult; Airway Resistance; Anti-Allergic Agents; Bronchodilator Agents; Budesonide; Cimetidine; Femal	1996
A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1995, Volume: 252, Issue:8 Topics: Administration, Inhalation; Adolescent; Adult; Cetirizine; Child; Histamine H1 Antagonists; Humans;	1995
Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Current medical research and opinion, 1995, Volume: 13, Issue:6 Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Butyrophenones; Female; Histami	1995
'Regular' versus 'as required' use of azelastine nasal spray in the treatment of seasonal allergic rhinitis. Advances in oto-rhino-laryngology, 1997, Volume: 51 Topics: Administration, Intranasal; Adult; Aerosols; Drug Administration Schedule; Female; Histamine H1 Anta	1997
Role of azelastine nasal spray in the symptomatic treatment of seasonal allergic rhinitis. Advances in oto-rhino-laryngology, 1997, Volume: 51 Topics: Administration, Intranasal; Adult; Aerosols; Aged; Drug Administration Schedule; Female; Histamine H	1997
Seasonal rhinitis and azelastine: long- or short-term treatment? The Journal of allergy and clinical immunology, 1997, Volume: 99, Issue:3 Topics: Administration, Intranasal; Adolescent; Adult; Double-Blind Method; Epithelial Cells; Epithelium; Fe	1997
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1997, Volume: 27, Issue:2 Topics: Adolescent; Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Method; Drug Adminis	1997
Efficacy of intranasally applied dimethindene maleate solution as spray in adult volunteers with symptoms of seasonal allergic rhinitis in the Vienna challenge chamber. Arzneimittel-Forschung, 1996, Volume: 46, Issue:8 Topics: Administration, Intranasal; Adult; Aerosols; Anti-Allergic Agents; Atmosphere Exposure Chambers; Cro	1996
A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1997, Volume: 254, Issue:5 Topics: Administration, Intranasal; Adult; Anti-Allergic Agents; Beclomethasone; Double-Blind Method; Female	1997
Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age. Arzneimittel-Forschung, 1997, Volume: 47, Issue:7 Topics: Administration, Intranasal; Child; Child, Preschool; Female; Histamine H1 Antagonists; Humans; Male;	1997
Efficacy and tolerability of azelastine nasal spray in the treatment of allergic rhinitis: large scale experience in community practice. Current medical research and opinion, 1997, Volume: 13, Issue:10 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Child;	1997
Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. International archives of allergy and immunology, 1997, Volume: 114, Issue:2 Topics: Adolescent; Adult; Allergens; Budesonide; Eosinophils; Female; Humans; Hypersensitivity, Immediate;	1997
Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:4 Topics: Administration, Inhalation; Administration, Intranasal; Administration, Oral; Adolescent; Adult; Age	1997
Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Current medical research and opinion, 1997, Volume: 14, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Conjunctivitis, Allergic; Dermatitis, Irritant; Doubl	1997
Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Current medical research and opinion, 1998, Volume: 14, Issue:3 Topics: Child; Child, Preschool; Conjunctivitis, Allergic; Double-Blind Method; Female; Histamine H1 Antagon	1998
Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. Allergy, 1998, Volume: 53, Issue:9 Topics: Adolescent; Adult; Conjunctivitis, Allergic; Double-Blind Method; Female; Histamine H1 Antagonists;	1998
[Clinical assessment of azelastine nasal spray in seasonal allergic rhinitis]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1998, Volume: 5, Issue:30 Topics: Administration, Intranasal; Adolescent; Adult; Female; Histamine H1 Antagonists; Humans; Male; Phtha	1998
Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 82, Issue:6 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Beclomethasone; Child	1999
Sequential therapy with azelastine in seasonal allergic rhinitis. Deutsche Rhinitis Studiengruppe (German Rhinitis Study Group). Arzneimittel-Forschung, 1999, Volume: 49, Issue:11 Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Arousal; Blood Proteins; Double-Blind Method; Eo	1999
Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2000, Volume: 30, Issue:2 Topics: Adult; Allergens; Alternaria; Anti-Allergic Agents; Asthma; Cross-Over Studies; Dermatitis, Atopic;	2000
[Acceptability of local treatment of allergic rhinitis with a combination of a corticoid (beclomethasone) and an antihistaminic (azelastine)]. Revue de laryngologie - otologie - rhinologie, 2000, Volume: 121, Issue:4 Topics: Administration, Inhalation; Adult; Beclomethasone; Drug Administration Schedule; Drug Therapy, Combi	2000
Comparative efficacy and safety of azelastine and levocabastine nasal sprays in patients with seasonal allergic rhinitis. Arzneimittel-Forschung, 2001, Volume: 51, Issue:5 Topics: Administration, Intranasal; Adult; Aerosols; Aged; Anti-Allergic Agents; Double-Blind Method; Endpoi	2001
Treatment of severe seasonal rhinoconjunctivitis by a combination of azelastine nasal spray and eye drops: a double-blind, double-placebo study. Journal of investigational allergology & clinical immunology, 2001, Volume: 11, Issue:1 Topics: Administration, Intranasal; Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Meth	2001
Effects of intranasal azelastine on the response to nasal allergen challenge. The Laryngoscope, 2002, Volume: 112, Issue:1 Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Inflammation Mediators; Male; Methac	2002
Effect of azelastine on the seasonal increase in non-specific bronchial responsiveness to methacholine in pollen allergic patients. A randomized, double-blind placebo-controlled, crossover study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1992, Volume: 22, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Allergens; Asthma; Bronchial Hyperreactivity; Double-Blind	1992
Azelastine reduces allergen-induced nasal response: a clinical and rhinomanometric assessment. European journal of clinical pharmacology, 1992, Volume: 42, Issue:2 Topics: Adult; Airway Resistance; Allergens; Female; Histamine H1 Antagonists; Humans; Male; Nose; Phthalazi	1992
The effect of intranasal azelastine, Rhinolast, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1992, Volume: 22, Issue:6 Topics: Administration, Intranasal; Adult; Allergens; Bronchodilator Agents; Female; Hemodynamics; Histamine	1992
Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis. The Journal of allergy and clinical immunology, 1988, Volume: 82, Issue:5 Pt 1 Topics: Adolescent; Adult; Chlorpheniramine; Circadian Rhythm; Clinical Trials as Topic; Dizziness; Double-B	1988

Article	Year
Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy. Immunity, inflammation and disease, 2022, Volume: 10, Issue:3 Topics: Fluticasone; Gene Expression; Humans; Phthalazines; Rhinitis, Allergic, Seasonal	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
In Brief: OTC azelastine nasal spray 0.15% (Astepro Allergy) for allergic rhinitis. The Medical letter on drugs and therapeutics, 2022, 10-31, Volume: 64, Issue:1662 Topics: Administration, Intranasal; Anti-Allergic Agents; Double-Blind Method; Histamine H1 Antagonists; Hum	2022
Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels. European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:20 Topics: Administration, Intranasal; Chemokine CCL26; Double-Blind Method; Humans; Mucins; Nasal Sprays; Rece	2023
Azelastine and fluticasone nasal spray: any advantage? Drug and therapeutics bulletin, 2014, Volume: 52, Issue:2 Topics: Administration, Intranasal; Adolescent; Adult; Androstadienes; Anti-Allergic Agents; Drug Combinatio	2014
[Socio-economic impact of allergic rhinitis and perspectives of appropriate therapy]. MMW Fortschritte der Medizin, 2014, Jul-24, Volume: 156 Suppl 2 Topics: Absenteeism; Administration, Intranasal; Adolescent; Adult; Androstadienes; Asthma; Child; Child, Pr	2014
IMPLICATION OF ALTERNATIVE MINIMAL CLINICALLY IMPORTANT DIFFERENCE THRESHOLD ESTIMATION METHODS ON TECHNOLOGY ASSESSMENT. International journal of technology assessment in health care, 2016, Volume: 32, Issue:6 Topics: Androstadienes; Anti-Allergic Agents; Humans; Minimal Clinically Important Difference; Phthalazines;	2016
Combination therapy with azelastine and fluticasone nasal sprays. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 101, Issue:1 Topics: Androstadienes; Anti-Allergic Agents; Drug Therapy, Combination; Fluticasone; Humans; Phthalazines;	2008
Azelastine (Astepro) nasal spray for allergic rhinitis. The Medical letter on drugs and therapeutics, 2009, Apr-20, Volume: 51, Issue:1310 Topics: Administration, Inhalation; Anti-Allergic Agents; Clinical Trials as Topic; Humans; Phthalazines; Rh	2009
Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. International archives of allergy and immunology, 2011, Volume: 155, Issue:1 Topics: Adult; Antigens, Plant; Cell Proliferation; Chemokine CCL17; Chemokine CCL22; Chlorpheniramine; Extr	2011
Development of a novel model for comparative evaluation of intranasal pharmacokinetics and effects of anti-allergic nasal sprays. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, Volume: 80, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Administration, Inhalation; Administration, Intranasal; Aero	2012
In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. Acta physiologica Hungarica, 2012, Volume: 99, Issue:2 Topics: Adult; Anti-Allergic Agents; Antioxidants; Asthma; Biomarkers; Case-Control Studies; Cells, Cultured	2012
[Respiratory allergies in the child and the adult]. La Revue du praticien, 2004, Jan-31, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag	2004
Nasal saline: placebo or drug? Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:1 Topics: Anti-Allergic Agents; Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; Lora	2004
Involvement of thromboxane A2 and histamine in experimental allergic rhinitis of guinea pigs. The Journal of pharmacology and experimental therapeutics, 1997, Volume: 280, Issue:3 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antigens; Benzoquinones	1997
Azelastine nasal spray for allergic rhinitis. The Medical letter on drugs and therapeutics, 1997, May-09, Volume: 39, Issue:1000 Topics: Administration, Intranasal; Aerosols; Drug Interactions; Histamine H1 Antagonists; Humans; Phthalazi	1997
[Efficacy of topical azelastine in the treatment of allergic rhinitis caused by Parietaria officinalis]. Recenti progressi in medicina, 1998, Volume: 89, Issue:4 Topics: Administration, Intranasal; Adult; Allergens; Data Interpretation, Statistical; Female; Histamine H1	1998
Azelastine does not adversely affect aerobic performance. The Journal of sports medicine and physical fitness, 1998, Volume: 38, Issue:3 Topics: Administration, Intranasal; Adolescent; Adult; Anaerobic Threshold; Anti-Allergic Agents; Conjunctiv	1998
Allergic rhinitis remains an important disease. The Journal of the American Osteopathic Association, 2002, Volume: 102, Issue:6 Suppl 2 Topics: Cromolyn Sodium; Histamine H1 Antagonists; Humans; Immunotherapy; Leukotriene Antagonists; Phthalazi	2002

azelastine and Hay Fever